BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Zachou K, Arvaniti P, Azariadis K, Lygoura V, Gatselis NK, Lyberopoulou A, Koukoulis GK, Dalekos GN. Prompt initiation of high-dose i.v. corticosteroids seems to prevent progression to liver failure in patients with original acute severe autoimmune hepatitis. Hepatol Res 2019;49:96-104. [PMID: 30248210 DOI: 10.1111/hepr.13252] [Cited by in Crossref: 27] [Cited by in F6Publishing: 28] [Article Influence: 6.8] [Reference Citation Analysis]
Number Citing Articles
1 Pape S, Schramm C, Gevers TJ. Clinical management of autoimmune hepatitis. United European Gastroenterol J 2019;7:1156-63. [PMID: 31700628 DOI: 10.1177/2050640619872408] [Cited by in Crossref: 15] [Cited by in F6Publishing: 10] [Article Influence: 5.0] [Reference Citation Analysis]
2 Zheng L, Liu Y, Shang Y, Han Z, Han Y. Clinical characteristics and treatment outcomes of acute severe autoimmune hepatitis. BMC Gastroenterol 2021;21:93. [PMID: 33648445 DOI: 10.1186/s12876-021-01653-4] [Reference Citation Analysis]
3 Sucher E, Sucher R, Gradistanac T, Brandacher G, Schneeberger S, Berg T. Autoimmune Hepatitis-Immunologically Triggered Liver Pathogenesis-Diagnostic and Therapeutic Strategies. J Immunol Res 2019;2019:9437043. [PMID: 31886312 DOI: 10.1155/2019/9437043] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]
4 De Martin E, Coilly A, Chazouillères O, Roux O, Peron JM, Houssel-Debry P, Artru F, Silvain C, Ollivier-Hourmand I, Duvoux C, Heurgue A, Barge S, Ganne-Carrié N, Pageaux GP, Besch C, Bourlière M, Fontaine H, de Ledinghen V, Dumortier J, Conti F, Radenne S, Debette-Gratien M, Goria O, Durand F, Potier P, Di Martino V, Reboux N, Ichai P, Sebagh M, Mathurin P, Agostini H, Samuel D, Duclos-Vallée JC; FILFOIE consortium – France. Early liver transplantation for corticosteroid non-responders with acute severe autoimmune hepatitis: The SURFASA score. J Hepatol 2021;74:1325-34. [PMID: 33503489 DOI: 10.1016/j.jhep.2020.12.033] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
5 Biewenga M, Inderson A, Tushuizen ME, Crobach ASLP, van Hoek B. Early Predictors of Short-Term Prognosis in Acute and Acute Severe Autoimmune Hepatitis. Liver Transpl 2020;26:1573-81. [PMID: 32997870 DOI: 10.1002/lt.25906] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
6 Arvaniti P, Giannoulis G, Gabeta S, Zachou K, Koukoulis GK, Dalekos GN. Belimumab is a promising third-line treatment option for refractory autoimmune hepatitis. JHEP Rep 2020;2:100123. [PMID: 32671332 DOI: 10.1016/j.jhepr.2020.100123] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 3.5] [Reference Citation Analysis]
7 Zachou K, Weiler‐normann C, Muratori L, Muratori P, Lohse AW, Dalekos GN. Permanent immunosuppression in SLA/LP‐positive autoimmune hepatitis is required although overall response and survival are similar. Liver Int 2020;40:368-76. [DOI: 10.1111/liv.14280] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
8 Rigopoulou EI, Gyftaki S, Arvaniti P, Tsimourtou V, Koukoulis GK, Hadjigeorgiou G, Dalekos GN. Autoimmune hepatitis in patients with multiple sclerosis: The role of immunomodulatory treatment. Clin Res Hepatol Gastroenterol 2019;43:e25-32. [PMID: 30594597 DOI: 10.1016/j.clinre.2018.12.002] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
9 Fujiwara K, Nakayama N, Kato N, Yokosuka O, Tsubouchi H, Takikawa H, Mochida S; Intractable Hepato-Biliary Diseases Study Group of Japan. Infectious complications and timing for liver transplantation in autoimmune acute liver failure in Japan: a subanalysis based on nationwide surveys between 2010 and 2015. J Gastroenterol 2020;55:888-98. [PMID: 32556645 DOI: 10.1007/s00535-020-01699-3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
10 Rahim MN, Miquel R, Heneghan MA. Approach to the patient with acute severe autoimmune hepatitis. JHEP Rep 2020;2:100149. [PMID: 32995712 DOI: 10.1016/j.jhepr.2020.100149] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
11 Dalekos GN, Gatselis NK, Zachou K. Acute Severe Autoimmune Hepatitis: Corticosteroids or Liver Transplantation? Liver Transpl 2019;25:1588-9. [PMID: 31359585 DOI: 10.1002/lt.25615] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
12 Rahim MN, Heneghan MA. Reply. Liver Transpl 2019;25:1457-8. [PMID: 31323692 DOI: 10.1002/lt.25606] [Reference Citation Analysis]
13 Efe C, Ozaslan E, Purnak T. What Is the Optimal Dose of Predniso(lo)ne for Induction of Remission in Patients With Autoimmune Hepatitis? Clin Gastroenterol Hepatol 2020;18:1896-7. [PMID: 30807845 DOI: 10.1016/j.cgh.2019.02.032] [Reference Citation Analysis]
14 Rahim MN, Heneghan MA. Reply. Liver Transpl 2019;25:1590-1. [PMID: 31344310 DOI: 10.1002/lt.25611] [Reference Citation Analysis]
15 Kimura N, Yamagiwa S, Sugano T, Horigome R, Setsu T, Tominaga K, Kamimura H, Takamura M, Terai S. Usefulness of chemokine C-C receptor 7- /programmed cell death-1+ follicular helper T cell subset frequencies in the diagnosis of autoimmune hepatitis. Hepatol Res 2019;49:1026-33. [PMID: 31020718 DOI: 10.1111/hepr.13356] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
16 Tanaka A. Autoimmune Hepatitis: 2019 Update. Gut Liver 2020;14:430-8. [PMID: 32301319 DOI: 10.5009/gnl19261] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 5.5] [Reference Citation Analysis]
17 Dalekos GN, Koskinas J, Papatheodoridis GV. Hellenic Association for the Study of the Liver Clinical Practice Guidelines: Autoimmune hepatitis. Ann Gastroenterol 2019;32:1-23. [PMID: 30598587 DOI: 10.20524/aog.2018.0330] [Cited by in Crossref: 3] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
18 Takahashi A, Ohira H. Autoimmune hepatitis, fatty liver, and Fukushima. Fukushima J Med Sci 2019;65:25-9. [PMID: 31270280 DOI: 10.5387/fms.2019-13] [Reference Citation Analysis]
19 Sakaguchi H, Mizuochi T, Haruta M, Takase R, Yoshida S, Yamashita Y, Nishikomori R. AIRE Gene Mutation Presenting at Age 2 Years With Autoimmune Retinopathy and Steroid-Responsive Acute Liver Failure: A Case Report and Literature Review. Front Immunol 2021;12:687280. [PMID: 34122451 DOI: 10.3389/fimmu.2021.687280] [Reference Citation Analysis]
20 Ikura A, Chu PS, Nakamoto N, Ojiro K, Taniki N, Yoshida A, Shinoda M, Morikawa R, Yamataka K, Noguchi F, Hoshi H, Usui S, Ebinuma H, Kitagawa Y, Saito H, Kanai T. CLIF-C Organ Failure Score and Liver Volume Predict Prognosis in Steroid-Treated Severe Acute Autoimmune Hepatitis. Hepatol Commun 2020;4:1019-33. [PMID: 32626834 DOI: 10.1002/hep4.1521] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
21 Rigopoulou EI, Dalekos GN. Current Trends and Characteristics of Hepatocellular Carcinoma in Patients with Autoimmune Liver Diseases. Cancers (Basel) 2021;13:1023. [PMID: 33804480 DOI: 10.3390/cancers13051023] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
22 Komori A. Recent updates on the management of autoimmune hepatitis. Clin Mol Hepatol 2021;27:58-69. [PMID: 33291862 DOI: 10.3350/cmh.2020.0189] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
23 Dalekos GN, Gatselis NK, Zachou K, Koukoulis GK. NAFLD and autoimmune hepatitis: Do not judge a book by its cover. Eur J Intern Med 2020;75:1-9. [PMID: 32051092 DOI: 10.1016/j.ejim.2020.02.001] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 4.0] [Reference Citation Analysis]
24 Rhodes JM, Schuster SJ, Furth EE, Kennard K, Nasta SD, Svoboda J, Porter DL, Mato AR. Management of giant cell hepatitis associated with chronic lymphocytic leukemia - a case series and review of the literature. Cancer Biol Ther 2019;20:1136-40. [PMID: 31091174 DOI: 10.1080/15384047.2019.1598763] [Cited by in Crossref: 2] [Article Influence: 0.7] [Reference Citation Analysis]
25 Rigopoulou EI, Gatselis N, Arvaniti P, Koukoulis GK, Dalekos GN. Alcoholic liver disease and autoimmune hepatitis: Sometimes a closer look under the surface is needed. Eur J Intern Med 2021;85:86-91. [PMID: 33451888 DOI: 10.1016/j.ejim.2020.12.024] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
26 Dalekos GN, Gatselis NK, Koukoulis GK. Non-alcoholic steatohepatitis or autoimmune hepatitis? Sometimes a closer look under the surface is needed. BMJ Case Rep 2020;13:e238400. [PMID: 33370951 DOI: 10.1136/bcr-2020-238400] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
27 Gatselis NK, Azariadis K, Lyberopoulou A, Dalekos GN. Programmed cell death-1 rs11568821 and interleukin-28B rs12979860 polymorphisms in autoimmune hepatitis. J Transl Autoimmun 2021;4:100126. [PMID: 34632357 DOI: 10.1016/j.jtauto.2021.100126] [Reference Citation Analysis]
28 Dalekos GN, Azariadis K, Lygoura V, Arvaniti P, Gampeta S, Gatselis NK. Autoimmune hepatitis in patients aged 70 years or older: Disease characteristics, treatment response and outcome. Liver Int 2021;41:1592-9. [PMID: 33896089 DOI: 10.1111/liv.14900] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]